TPST 241220 2.50C (TPST241220C2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

TPST241220C2500

Watchlist

0.05
0.000.00%

15min DelayClose Nov 25 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire16:30 ET
Tempest Therapeutics Is Maintained at Overweight by Piper Sandler
Dow JonesNov 13 12:00 ET · Ratings
Piper Sandler Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsNov 13 08:31 ET · Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
TipRanksNov 13 07:32 ET · Ratings
Scotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
TipRanksNov 13 07:30 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
BenzingaNov 13 07:25 ET

Comments

Chasing_Freedom

Nov 22 14:49

$Tempest Therapeutics (TPST.US)$ ugh consolidation is over valued should be under guess we gotta be ready for the dip

CommonCentsVet

Nov 19 06:56

$Tempest Therapeutics (TPST.US)$ Hey good morning guys and gals. I am definitely 100% on board with this I believe it has a lot of potential but but but but. Keep in mind it's got a reverse split coming for 1/2 or 1/15 I sold half to have plenty of ammunition to buy in when it dips. I'm looking for ¢ .70 or under. I don't see this is a bad thing. NFA Just my two pennies worth.

74483586

Nov 15 14:04

$Tempest Therapeutics (TPST.US)$ if you would like to gamble on this kind of growth company, you must be well prepared for the dip and loss or holding for the long term. Complaining doesn't help.

Teddy123

Nov 13 06:24

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

$Tempest Therapeutics (TPST.US)$
13/11/2024 - 05:21
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC
Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial
Received final funding approval from NCI to move TPST-1495 into a Phas...

小竜

Nov 12 09:38

$Tempest Therapeutics (TPST.US)$